11 protocols meet the specified criteria

OCR13631

Molecular Analysis for Therapy Choice (MATCH)

OCR15732

Phase II Trial of the PARP1 Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)

OCR16587

Feasibility, Acceptability, and Efficacy of a Yoga Intervention for Distress in Women with Gynecologic, Gastrointestinal, or Thoracic Cancer

OCR17458

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors (SGNTV-001)

OCR17893

Palliative Care for Elderly Outpatients

OCR18617

A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

OCR20388

A Randomized Pragmatic Trial of Genotype-Guided Supportive Care in Symptom Treatment of Cancer Patients (UF-ETG-002)

OCR23042

A Dose-optimization, Exploratory Phase Ib/II Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143, When Given in Combination With the Anti-PD-1 Antibody Nivolumab in Patients With Specific Solid Tumors Who Have Progressed During or Immediately After Anti-PD-1/PD-L1 Treatment

OCR26182

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b

OCR26922

A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm)and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

OCR33027

Effect of position and anesthetic choice in intraocular pressure in robotic GYN oncology patients